Debiopharm is proud to be the co-lead investor in the Belgian startup Oncomfort, to scale up its Virtual Reality Digital Sedation™. Debiopharm led this investment together with Credit Mutuel Innovation and will join Oncomfort’s board of directors.
This investment is perfectly in line with our strategy to support companies that will improve cancer patient journey. Through virtual reality, Oncomfort Digital Sedation™ new technology can be used to relieve patients’ pain and anxiety. As Thierry Mauvernay, President of Debiopharm stated:
With this investment in Oncomfort, we really wanted to push the boundaries to inspire healthcare stakeholders to acknowledge that there is much more we can do for patients through digital technology.
Click here to access the full press release
